Biocompatibility Evaluation Requirements for Medical Devices in Egypt

1. Key takeaways

Egypt’s management of biocompatibility consists of one qualification requirement plus four reassessment triggers. The qualification requirement: biocompatibility studies must be performed by an accredited entity, the entity’s qualification/accreditation certificate issued under ISO/IEC 17025 must be submitted, its accreditation scope must be shown to cover the tests performed, and the results remain the responsibility of the manufacturing enterprise. The four triggers: a change of raw materials (the biocompatibility study must be re-evaluated by the stability scientific committee), a change of sterilization method (a new stability study containing sterilization verification plus a biological risk reassessment), a change of packaging material or packaging size (a new stability study containing packaging verification plus a biological risk reassessment), and a change of shelf life and/or storage conditions (evaluated by the stability scientific committee). What distinguishes Egypt from many other markets is where the review weight sits: not on the list of tests performed, but on who performed them and under what accreditation.

2. Legal basis

3. Expert insights

Insight 1: Egypt places the compliance weight of biocompatibility on who did the work, not on what was done.

The Fifth item does not enumerate a biocompatibility test list; it requires performance by an accredited entity and submission of the ISO/IEC 17025 qualification certificate with proof of the accreditation scope. This differs from the EU’s item-by-item evaluation under the ISO 10993 series: the company’s burden of proof centers on the laboratory’s qualification chain, so assembling that chain is the first task, not the last.

Insight 2: responsibility is written into the guideline — the results are the manufacturing enterprise’s responsibility.

The closing sentence of the Fifth item: the results of the above tests are the responsibility of the manufacturing enterprise. Outsourcing therefore does not transfer responsibility; when a problem arises, EDA pursues the manufacturer, not the laboratory.

Insight 3: the sterilization method is a mandatory field inside the biocompatibility documentation.

The Sixth item: all studies related to the sensitization and irritation tests (Sensitization & Irritation tests) must clearly state the sterilization method of the tested device. Together with the sterility requirement of Section 4.1, the sterilization-method change clause of the change guideline, and the sterilization-method marking in the labelling guideline, this field is interrogated at four separate points in the Egyptian system.

Insight 4: the four triggers cover the product’s full life cycle, and each carries a biological risk reassessment.

Among the four triggers of Section 10, a sterilization method change and a packaging material/size change both require a new stability study plus a biological risk reassessment; a raw material change requires a re-evaluation of the biocompatibility study; a shelf life/storage condition change is evaluated by the stability committee. Note that the first two are worded as biological risk reassessments, which is not the same action as the biocompatibility study re-evaluation triggered by a raw material change — the former is a risk analysis, the latter is a redo of testing.

Insight 5: reference-country status brings one explicit exemption.

The Seventh item: devices imported from a reference country and submitted to the change department are exempt from submitting the biocompatibility study when presented to the stability and biocompatibility specialized scientific committee. Chinese manufacturers do not benefit, but the rule explains why a reference-country FSC carries value in Egypt beyond the certificate itself.

Insight 6: the April 16, 2026 circular creates a stacking effect.

EDA announced on April 16, 2026 that local factories holding CE certificates submitting registration or re-registration dossiers are exempted from submitting the reference-country FSC, stability studies and biocompatibility test reports, while EDA retains the right to request them. (Practical estimate: the scope of application and implementation details of the circular follow the current official notice on the EDA website.) For factories that are both local and CE-holding, the stability and biocompatibility obligations of Sections 6 and 10 can be substantially reduced.

Insight 7: the retention sample obligation of local factories is bound to the biocompatibility file.

Section 6, First requires that when local factories submit stability studies, samples must be sealed by the Central Administration of Pharmaceutical Institutions Inspection, stamped by the entity performing the study, bear batch numbers consistent with the stability study, and be retained at the factory for the validity period of the registration licence. Although the clause text targets stability studies, retention samples of the same batch in practice also become the verification anchor for biocompatibility documentation.

4. Practical recommendations

1. Build the laboratory qualification package first: ISO/IEC 17025 certificate plus proof of accreditation scope — both are indispensable.
2. Retain the manufacturing enterprise’s responsibility statement: confirm the allocation of responsibility for outsourced tests in writing in the dossier.
3. State the sterilization method in every sensitization and irritation study.
4. Maintain a change-to-biocompatibility mapping table covering raw material, sterilization method, packaging material/size, and shelf life/storage conditions.
5. Distinguish the re-evaluation of a biocompatibility study from the reassessment of biological risk: the former means redoing tests, the latter is a risk analysis.
6. Local factories: assess the exemption effect of the 2026-04-16 CE circular and keep a contingency plan for EDA requests.
7. Set up retention sample management and a batch number ledger in parallel.

5. Verification checklist

• □ Biocompatibility studies performed by an accredited entity
• □ ISO/IEC 17025 qualification certificate and proof of accreditation scope submitted
• □ Manufacturing enterprise responsibility statement confirmed in writing
• □ Sensitization and irritation tests state the sterilization method
• □ The four change triggers incorporated into the change management system
• □ Distinction established between biocompatibility study re-evaluation and biological risk reassessment
• □ Local factories assessed the 2026-04-16 CE circular exemption with a contingency plan

Regulatory information verified as of October 29, 2026, per the current text of Section 6, Fifth/Sixth/Seventh and Section 10 of EDREX: GL.CAMD.002 Version 2.

• Local resources in Egypt: GRZAN supports manufacturers from the Chinese mainland and overseas in dealing with the Egyptian Drug Authority (EDA) on medical device registration, import approval and change applications, including registration applicant scheme design (import company / local factory / scientific office), scientific committee evaluation preparation, reference-country free sale certificate route argumentation, Arabic labelling and IFU localization, and vigilance system and periodic reporting set-up.
• Service capabilities: product attribute and risk classification (device Class I–III / IVD Class A–D), registration and re-registration, system and bundled registration applicability, three-category change determination, import approval and the annual import plan, vigilance reports and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.